Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE Trial
- 1 July 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (13), 3172-3181
- https://doi.org/10.1158/1078-0432.ccr-19-3056
Abstract
Purpose: The incidence of lung cancer has dramatically increased in women. Preclinical data have suggested that combining EGFR-TKI with an anti-estrogen may overcome resistance to EGFR-TKI. Experimental Design: The IFCT-1003 LADIE trial was a 2x2 arms parallel open-label randomized phase II trial. EGFR-TKI-naïve post-menopausal women with advanced lung cancer were treated with gefitinib (G) vs. G + fulvestrant (G+F) in the EGFR mutated group (EGFR+) or with erlotinib (E) vs. E + fulvestrant (E+F) in the EGFR wild-type group (EGFR-WT). The primary objective was progression-free survival (PFS) at 3 and 9 months for EGFR-WT and EGFR+ patients. Results: Overall, 204 patients and 175 patients were enrolled in the EGFR+ and EGFR-WT cohorts. In the EGFR+ cohort, the primary endpoint was reached, with 58% of the G+F group patients being non-progressive at 9 months. Adding F to G was not associated with improved PFS (9.9 vs 9.4 months) or OS (22.1 vs 28.6 months). In the EGFR-WT cohort, the primary endpoint was also achieved (33.7% of the patients were non-progressive at 3 months). Adding F to E was not associated with improved outcome (PFS 1.8 vs 2.0 and OS 10.3 vs 7.3 months). No PFS difference was observed regarding Estrogen Receptor alpha expression. The tolerance was as expected with no treatment-related death. Conclusions: Adding fulvestrant to EGFR-TKI is feasible, but not associated with prolonged PFS regardless EGFR status. The lack of benefits while combining fulvestrant to EGFR-TKI does not support its future development in unselected population.Keywords
Funding Information
- AstraZeneca
- Roche
- Ligue Contre le Cancer
This publication has 22 references indexed in Scilit:
- Lung Cancer and Hormone Replacement Therapy: Association in the Vitamins and Lifestyle StudyJournal of Clinical Oncology, 2010
- Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trialThe Lancet, 2009
- Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancerLung Cancer, 2009
- Association Between Estrogen Receptor-β Expression and Epidermal Growth Factor Receptor Mutation in the Postoperative Prognosis of Adenocarcinoma of the LungJournal of Clinical Oncology, 2009
- Hormone Replacement Therapy Is Associated With Decreased Survival in Women With Lung CancerJournal of Clinical Oncology, 2006
- The significance of estrogen receptor β in 301 surgically treated non–small cell lung cancersThe Journal of Thoracic and Cardiovascular Surgery, 2005
- Nuclear Estrogen Receptor β in Lung Cancer: Expression and Survival Differences by SexClinical Cancer Research, 2005
- Estrogen Receptor α and β are Prognostic Factors in Non–Small Cell Lung CancerClinical Cancer Research, 2005
- Combined Targeting of the Estrogen Receptor and the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer Shows Enhanced Antiproliferative EffectsCancer Research, 2005
- Familial aggregation of breast cancer with early onset lung cancerGenetic Epidemiology, 1999